Skip to main content
SpringerLink
Log in

Quantitative HBsAg titer as predictor of response to therapy

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

The expanding availability of different potent antiviral agents for the treatment of chronic hepatitis B (CHB) has created optimism for achieving treatment goals, such as the loss of serum hepatitis B surface antigen (HBsAg), which represents the closest-to-cure outcome of chronic hepatitis B virus infection. Recent studies indicated the potential usefulness of HBsAg quantification during antiviral therapy (especially with interferon-α-based regimens) as a potential predictor of virologic response. This article critically reviews the most recent data regarding the value of measurements of HBsAg concentrations in predicting response in patients with hepatitis B e antigen (HBeAg)-positive and HBeAg-negative CHB treated with different antiviral agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227–242.

    Article  CAS  PubMed  Google Scholar 

  2. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507–539.

    Article  CAS  PubMed  Google Scholar 

  3. Fattovich G, Giustina G, Sanchez-Tapias J, et al.: Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) [see comments]. Am J Gastroenterol 1998, 93:896–900.

    Article  CAS  PubMed  Google Scholar 

  4. Deguchi M, Yamashita N, Kagita M, et al.: Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004, 115:217–222.

    Article  CAS  PubMed  Google Scholar 

  5. van Helden J, Denoyel G, Karwowska S, et al.: Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System. Clin Lab 2004, 50:63–73.

    PubMed  Google Scholar 

  6. Muhlbacher A, Weber B, Burgisser P, et al.: Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 2008, 197:55–64.

    Article  CAS  PubMed  Google Scholar 

  7. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ: Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007, 12:73–82.

    CAS  PubMed  Google Scholar 

  8. Moucari R, Mackiewicz V, Lada O, et al.: Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151–1157.

    Article  CAS  PubMed  Google Scholar 

  9. Brunetto MR, Moriconi F, Bonino F, et al.: Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141–1150.

    Article  CAS  PubMed  Google Scholar 

  10. Perrillo RP: Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns. Hepatology 2009, 49:1063–1065.

    Article  CAS  PubMed  Google Scholar 

  11. Blumberg BS, Alter HJ, Visnich S: A “new” antigen in leukemia sera. JAMA 1965, 191:541–546.

    CAS  PubMed  Google Scholar 

  12. Seeger C, Mason WS: Hepatitis B virus biology. Microbiol Mol Biol Rev 2000, 64:51–68.

    Article  CAS  PubMed  Google Scholar 

  13. Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW: Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994, 23:251–257.

    Article  CAS  PubMed  Google Scholar 

  14. Zoulim F, Mimms L, Floreani M, et al.: New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. J Clin Microbiol 1992, 30:1111–1119.

    CAS  PubMed  Google Scholar 

  15. Dandri M, Murray JM, Lutgehetmann M, et al.: Virion halflife in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology 2008, 48:1079–1086.

    Article  PubMed  Google Scholar 

  16. Kohmoto M, Enomoto M, Tamori A, et al.: Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005, 75:235–239.

    Article  CAS  PubMed  Google Scholar 

  17. Chan HL, Wong VW, Tse AM, et al.: Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007, 5:1462–1468.

    Article  CAS  PubMed  Google Scholar 

  18. Werle-Lapostolle B, Bowden S, Locarnini S, et al.: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750–1758.

    Article  CAS  PubMed  Google Scholar 

  19. Wursthorn K, Lutgehetmann M, Dandri M, et al.: Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675–684.

    Article  CAS  PubMed  Google Scholar 

  20. Borgniet O, Parvaz P, Bouix C, et al.: Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol 2009, 81:1336–1342.

    Article  CAS  PubMed  Google Scholar 

  21. Volz T, Lutgehetmann M, Wachtler P, et al.: Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007, 133:843–852.

    Article  CAS  PubMed  Google Scholar 

  22. Jaroszewicz J, Calle Serrano B, Deterding K, et al.: HBsAg serum levels are associated with the phase of HBV-infection. J Hepatol 2009, 50(Suppl 1):S139.

    Article  Google Scholar 

  23. Chen J, Wang Z, Guo Y, et al.: Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral Res 2009, 81:88–91.

    Article  CAS  PubMed  Google Scholar 

  24. Wursthorn K, Jung M, Manns M, et al.: Kinetics of HBsAg decline in HBeAg+ chronic hepatitis B patients with 3 years of telbivudine treatment during the GLOBE study. J Hepatol 2009, 50(Suppl1):S9.

    Article  Google Scholar 

  25. Lau GK, Marcellin P, Brunetto M et al.: On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009, 50(Suppl 1):S333.

    Article  Google Scholar 

  26. Takkenberg B, Zaajer H, Weegink C et al.: Baseline HBsAg level predict HBsAg loss in chronic hepatitis B patients treated with a combination of peginterferon alfa-2a and adefovir: an interim analysis. J Hepatol 2009, 50(Suppl 1):S8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, 115 26, Athens, Greece

    Stephanos J. Hadziyannis

Authors
  1. Emilia Hadziyannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitrios Vassilopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephanos J. Hadziyannis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanos J. Hadziyannis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hadziyannis, E., Vassilopoulos, D. & Hadziyannis, S.J. Quantitative HBsAg titer as predictor of response to therapy. Curr hepatitis rep 8, 169–172 (2009). https://doi.org/10.1007/s11901-009-0024-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-009-0024-8

Keywords

Search

Navigation